Mantle Cell Lymphoma International Prognostic Index (MIPI)

ورودی‌های بالینی بیمار

حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years

حداقل ۵۰ — حداکثر ۱۰۰۰۰ • واحد: U/L

حداقل ۱۵۰ — حداکثر ۴۰۰ • واحد: U/L

حداقل ۱ — حداکثر ۵۰۰ • واحد: ×10³/μL

حداقل ۰ — حداکثر ۱۰۰ • واحد: %

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
mipi score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–5.7
  • Intermediate Risk5.7–6.2
  • High Risk6.2–20
Direct Clinical Answer

The Mantle Cell Lymphoma International Prognostic Index (MIPI) calculator is designed for bedside predicting survival in mantle cell lymphoma patients using age, performance status, lactate dehydrogenase level, and white blood cell count in clinical practice. The resulting score directly guides clinician decision-making regarding initiating targeted.

Clinical Guidelines & Evidence

Predicts survival in mantle cell lymphoma patients using age, performance status, lactate dehydrogenase level, and white blood cell count. More specific to mantle cell lymphoma than the International Prognostic Index (IPI). Stratifies patients into low, intermediate, and high risk categories for prognostic planning and treatment decisions.

Clinical Indication

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is indicated for bedside clinical practice to support Predicts survival in mantle cell lymphoma patients using age, performance status, lactate dehydrogenase level, and white blood cell count. More specific to mantle cell lymphoma than the International Prognostic Index (IPI). Stratifies patients into low, intermediate, and high risk categories for prognostic planning and treatment decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Most mantle cell lymphoma patients require treatment at diagnosis regardless of risk group.

Formula & Variables:

MIPI = (0.03535 × age in years) + 0.6978 (if ECOG PS 2-4) + [1.367 × log10(LDH/ULN)] + [0.9393 × log10(WBC in ×10³/μL)]. MIPIb (biological MIPI) = MIPI + (0.02142 × Ki-67 index %) when Ki-67 is available.

Input Parameters

NameTypeRequiredDescription
ageintegerYesPatient age in years. Age is a continuous variable in the MIPI formula and significantly impacts prognosis(years)
ecog_performance_statusstringYesECOG Performance Status scale measuring patient's functional status and ability to perform daily activities
serum_ldhfloatYesSerum lactate dehydrogenase level in U/L. Elevated LDH indicates tissue damage, cellular turnover, or disease burden(U/L)
ldh_upper_limit_normalfloatYesLaboratory's upper limit of normal for serum LDH in U/L. Typically ranges from 200-250 U/L depending on laboratory and methodology(U/L)
white_blood_cell_countfloatYesWhite blood cell count in cells per microliter (×10³/μL). Elevated WBC may indicate disease burden or bone marrow involvement(×10³/μL)
ki67_indexfloatNoKi-67 proliferation index as percentage (0-100%). Optional parameter for calculating biological MIPI (MIPIb). Higher Ki-67 indicates more aggressive disease(%)

Score Interpretation & Guidance

RangeStageDescription
0–5.7Low RiskLow risk for poor prognosis
5.7–6.2Intermediate RiskIntermediate risk for poor prognosis
6.2–20High RiskHigh risk for poor prognosis

Evidence-Based References (EBM)

  • Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008 Jan 15;111(2):558-65. doi: 10.1182/blood-2007-06-095331.DOI: 10.1182/blood-2007-06-095331
  • Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, Trneny M, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014 May 1;32(13):1338-46. doi: 10.1200/JCO.2013.52.2466.DOI: 10.1200/JCO.2013.52.2466
  • Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008 Oct 1;112(7):2687-93. doi: 10.1182/blood-2008-03-147025.DOI: 10.1182/blood-2008-03-147025

Related calculators